Skip navigation
Skip navigation

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

Friedman, Scott L.; Ratziu, Vlad; Harrison, Stephen A.; Abdelmalek, Manal F.; Aithal, Guruprasad P.; Caballeria, Juan; Francque, Sven; Farrell, Geoffrey; Kowdley, Kris V.; Craxi, Antonio; Simon, Krzysztof; Fischer, Laurent; Melchor-Khan, Liza; Vest, Jeffrey; Wiens, Brian L.; Vig, Pamela; Seyedkazemi, Star; Goodman, Zachary; Wong, Vincent Wai-Sun; Loomba, Rohit; Tacke, Frank; Sanyal, Arun; Lefebvre, Eric


The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C-C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis (LF). A randomized, double-blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fatty liver disease activity score (NAS) ≥4, and LF (stages 1-3, NASH Clinical Research Network) at 81 clinical sites. Subjects (N = 289) were randomly assigned CVC 150 mg or placebo. Primary outcome...[Show more]

CollectionsANU Research Publications
Date published: 2018
Type: Journal article
Source: Hepatology (Baltimore, Md.)
DOI: 10.1002/hep.29477
Access Rights: Open Access


File Description SizeFormat Image
Friedman_et_al-2018-Hepatology.pdf669.84 kBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator